Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23195)	7/14/1998 3:14:00 PM
From: Mudcat	Respond to of 32384

<They have drawn experienced management from the pharmas, so although this is LGND's first NDA, I expect it to go quite smoothly.> I guess this will provide a good test case to see just how good Lgnd's management really is? Based on the experience they hopefully picked up from the ONTAK delay, I would hope it goes smoothly.

To: Henry Niman who wrote (23195)	7/14/1998 9:09:00 PM
From: Void	Read Replies (3) \| Respond to of 32384

Re: GCSF mimic There may be a market in mice but there doesn't appear to be one in humans. SOURCE: BioWorld Today DATE: July 14, 1998 "Although this compound does have, we believe, incredible effects in the mouse," Rosen observed, "in the assays we've done to date we have not seen activity in human systems. So we're going back to several drawing boards, looking at related molecules from the same series as well as discovery of additional ones that will be human-active." For those who don't know, "Rosen is senior director of transcription research at Ligand Pharmaceuticals Inc., in San Diego, Calif., and senior author of a paper in the current issue of Science, dated July 10, 1998." I would be interested to know if LGND is planning on entering the clinic with this.